<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02849795</url>
  </required_header>
  <id_info>
    <org_study_id>ADIPSO</org_study_id>
    <nct_id>NCT02849795</nct_id>
  </id_info>
  <brief_title>Evaluation of Adipokines and Fat Tissue in Psoriasis and Psoriatic Arthritis</brief_title>
  <acronym>ADIPSO</acronym>
  <official_title>Evaluation of Adipokines and Fat Tissue in Psoriasis and Psoriatic Arthritis and Assessment of Their Relations With the Risk of Cardiovascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Body composition analysis and especially body fat distribution in regions of interest&#xD;
      (android and in particular intra-abdominal region) provides some information on the risk of&#xD;
      cardiovascular disease. There is little data available on the body composition analysis in&#xD;
      psoriasis and psoriatic arthritis (diseases with higher risk of cardiovascular disease), in&#xD;
      particular data on fat distribution in regions of interest regarding the risk of&#xD;
      cardiovascular disease.&#xD;
&#xD;
      Adipokines, secreted by the adipose tissue, have pro or anti-inflammatory and metabolic&#xD;
      properties that are interesting to explore in pathologies with a higher risk of&#xD;
      cardiovascular disease like psoriasis or psoriatic arthritis.&#xD;
&#xD;
      Adipokines have been investigated in psoriasis but fat tissue and in particular its&#xD;
      distribution (android/visceral or intra-abdominal) has not been studied in parallel.&#xD;
      Moreover, relation between adipokines and psoriasis area or severity has been studied but the&#xD;
      relation between adipokines and cardiovascular risk factors has not yet been investigated.&#xD;
&#xD;
      The aim of this study is to investigate relations between the body fat distribution,&#xD;
      adipokines rates and the risk of cardiovascular disease of these patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">October 17, 2017</completion_date>
  <primary_completion_date type="Actual">October 17, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Android fat distribution measured by bone densitometry (DEXA) (LUNAR GE iDXA device)</measure>
    <time_frame>day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body fat</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body masses</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-abdominal body fat mass (measured by CoreScan)</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gynoid distribution of body fat</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SCORE (Systematic COronary Risk Evaluation).</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>levels of adipokines</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Homeostasis model assessment of insulin resistance</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone mineral density of rachis, femoral neck, whole body</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>levels of ghrelin</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">199</enrollment>
  <condition>Psoriasis</condition>
  <condition>Arthritic Psoriasis</condition>
  <arm_group>
    <arm_group_label>Psoriasis and arthritic psoriasis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>additional blood sample for biological analyses bone densitometry questionnaires</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>bone densitometry</intervention_name>
    <arm_group_label>Psoriasis and arthritic psoriasis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaires</intervention_name>
    <arm_group_label>Psoriasis and arthritic psoriasis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>biological analyses</intervention_name>
    <arm_group_label>Psoriasis and arthritic psoriasis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosis of psoriasis vulgaris or psoriasis pustulosa confirmed by a dermatologist or&#xD;
             a diagnosis of psoriatic arthritis (CASPAR criteria) confirmed by a rheumatologist&#xD;
&#xD;
          -  Age ≥ 18 and ≤ 80 years old&#xD;
&#xD;
          -  Control group: patients matching with sex, age ± 5 years, BMI (4 groups), coming to&#xD;
             the same hospital for a consultation.&#xD;
&#xD;
        (BMI groups : BMI &lt; 18,5 kg/m²; 18,5 ≤ BMI ≤ 24,99 kg/m²; 25≤ BMI ≤ 29,99 kg/m²; BMI ≥ 30&#xD;
        kg/m²) Control group patients for psoriatic arthritis will be included during a&#xD;
        rheumatologist consultation. They may have a non-inflammatory common disco-vertebral&#xD;
        pathology (lumbago, lumbosciatic, spinal stenosis, neck pain, cervical arthritis and&#xD;
        cervicobrachial neuralgia).&#xD;
&#xD;
        Control group patients for psoriasis will be included during a dermatologist consultation.&#xD;
        They may have a non-inflammatory skin disease (acne, acne rosacea, idiopathic Raynaud's&#xD;
        phenomenon, basal cell carcinoma, acanthosis nigricans).&#xD;
&#xD;
        In case of recruitment difficulties, healthy volunteers can be included.&#xD;
&#xD;
          -  Postmenopausal women (for at least 24 months), surgically sterilized, or for women of&#xD;
             childbearing age, efficacy use of contraceptive methods (contraceptive pills,&#xD;
             injections or patches, intra-uterine device, double-barrier contraception),&#xD;
&#xD;
          -  Signature of informed consent form&#xD;
&#xD;
          -  French social security Affiliation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant woman&#xD;
&#xD;
          -  Corticosteroid therapy &gt;10 mg of prednisone or equivalent /day&#xD;
&#xD;
          -  Patients taking biological therapy (anti-TNFalpha therapy: infliximab, etanercept,&#xD;
             adalimumab, golimumab, certolizumab ; anti-Interleukin-12/Interleukin-23:&#xD;
             ustekinumab).&#xD;
&#xD;
          -  Legal incapacity or limited legal capacity&#xD;
&#xD;
          -  Presence of any condition hampering compliance with the study protocol, at the&#xD;
             discretion of the investigator&#xD;
&#xD;
          -  No french social security affiliation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chru Besancon</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>July 27, 2016</study_first_submitted>
  <study_first_submitted_qc>July 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2016</study_first_posted>
  <last_update_submitted>February 9, 2018</last_update_submitted>
  <last_update_submitted_qc>February 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity, Abdominal</keyword>
  <keyword>Adipokines</keyword>
  <keyword>Risk of cardiovascular diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

